Page 769 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

Index 753

ollicular lymphoma (FL), 429, 429 disposal considerations, 712 pathophysiology, 284
lymphoplasmacytic lymphoma, 430–431 ecological in ormation, 711–712 physiology, 283

mantle cell lymphoma (MCL), 429–430 exposure controls and personal protection, RBC, 280–281
marginal zone B-cell lymphoma, 430 710–711 testing, 286t
not otherwise speci ed (NOS), 431 re ghting measures, 710 treatment and monitoring therapy, 286–287
pathophysiology, 428 rst aid measures, 710 vitamin B /cobalamin
12
Lymphoplasmacytic lymphoma, 430–431 handling and storage, 710 de ciencies, 282b, 284, 286
bone marrow aspirate, 441, 441 hazards identi cation, 709 physiology, 283
clinical signs and symptoms, 441 identi cation, 709 potential causes, 287b
epidemiology, 440 physical and chemical properties, 711 transport, 283–284

laboratory characteristics, 430–431 regulatory in ormation, 712 Megaloblastic maturation, 111
pathophysiology, 441 sa ety rating, other in ormation, 712 Meiosis, 70, 70–71
treatment, 441 stability and reactivity, 711 Melting curve analysis (MCA), 658
Lymphopoiesis, 91 toxicological in ormation, 711 Memory cells, 194

Lymphoproli erative condition, 356 transport in ormation, 712 Merozoites, 153
Lymphoproli erative disorders classi cation, 416, Maturation-storage compartment, 165, 165 Mesoderm migration, 82
417t Maturation time correction actor, 215t Mesothelial cells, 590
Lysosomal storage diseases, 344–345 Mature erythrocyte, 111 Metamyelocyte, 165, 167–168, 168

Lysosomes, 62, 495, 544 Mature lymphocyte, 193, 195 Metaphase, 68, 68b
Mature platelets, 493 Metaplasia, 61, 62
M cellular ultrastructure o Metarubricyte, 109, 109
M phase, mitosis, 68 contractile proteins, 495 Methemalbumin, 133

Macrocytic anemias, 231, 231–232, 232b, 280–281, cytoplasmic membrane, 495 Methemoglobin, 129
281b glycocalyx, 495, 495 Methemoglobin reductase de ciency, 300
Macrocytic erythrocyte, 142 granules, 495 Methemoglobin reductase pathway, 114–115
Macrocytosis, 142–143, 231, 231–232, 232b, micro laments and microtubules, 495 Methemoglobinemia, 115, 328

280–281, 281b development, 493–494 Microangiopathic red cell destruction, 301
Macrogametes, 152 megakaryocytes, 493 Microarray gene chip technology, 665, 666
Macrophage-monocytic series, 165 Maurer dots, 154 Microbodies, 62
Macrophages, 91–92 May-Hegglin anomaly, 340t, 342, 342, 515, 515 Microcytic anemias, 232

acute in ammatory response, 174–175 MCH (see Mean corpuscular hemoglobin) Microcytic erythrocyte, 142
development, 236-237, 169–170 MCHC (see Mean corpuscular hemoglobin Microcytic hypochromic anemia, 232
unctions, 170, 171 concentration) Microcytosis, 143–144
kinetics, 170 MCV (see Mean corpuscular volume) Microcytosis and hypochromia in iron de ciency

li e span MDS/MPN (see Myelodysplastic syndromes anemia, 231, 231
circulatory phase, 172 (MDS); Myeloproli erative neoplasms Micro laments, 62
tissue phase, 172–173 (MPNs)) Microgametes, 152
morphological characteristics, 172, 589 Mean corpuscular hemoglobin (MCH), 213, 284, Microglial cells, 169

movement, 177 676 Microhematocrit method, 284, 674–675
production, 170 Mean corpuscular hemoglobin concentration MicroRNA, 388, 421
pulmonary alveolar, 171–172 (MCHC), 213–214, 284, 676 Microscope
role o , 174 Mean corpuscular volume (MCV), 212, 280, 284, equipment and supplies, 722

Major histocompatibility complex (MHC ) class 628, 628t, 629, 629t, 676 exterior, 723
II, 178 Mean peroxidase index (MPXI), 632 light source and condense, 723
Malaria Mean platelet volume (MPV), 624 objectives, 723
diagnosis, 153 Mean platelet volume calculation, 631, 631 ocular, 723

disease cycle Mean platelet volume disorders, 631, 631t optical lenses, 723
humans, 153, 153 Measles, 245 procedural steps, 722–723
mosquito, 152, 153 Median cubital vein, 39 stage and adjustment knobs, 723
etiology, 152 Megakaryoblastic leukemia, 394 uses, 722

molecular testing, 154 Megakaryoblasts, 97 Microtubules, 62
morphological eatures, 153t Megakaryocytes, 492 Migration inhibition actor (MIF), 201
Plasmodium falciparum, 154–155, 155 Megakaryocytic cell series Miller ocular disc, 677
Plasmodium malariae, 155, 155 bone marrow megakaryocytes, 493, 493 Minimal residual disease (MRD), 74, 421, 456, 654

Plasmodium ovale, 155, 155–156 endoreduplication, 493 Mitochondria, 62
Plasmodium vivax, 154, 154 mature platelets, 494–495, 495 Mitogen, 65
smears, 683–685, 684, 684t cellular ultrastructure o , 494–495, 495 Mitosis, 67
symptoms, 153 megakaryocytes, 494, 494, 494t G0 phase, 68

Malignant cells, 589 platelet kinetics, li e span, and normal values, interphase, 66–67
Mantle cell lymphoma (MCL) 495–496 M phase, 68
clinical signs and symptoms, 430 Megakaryopoiesis, 91 Mitotic pool, 165
laboratory characteristics, 430 Megaloblastic, 281 Mixing study, 535

pathophysiology, 430 Megaloblastic anemias, 280 Molecular genetics, hematology
prognosis, 430 bone marrow aspirate smear, 285 allele-speci c oligonucleotide PCR (ASO-PCR),
in situ mantle cell neoplasia ISMCN), 429 causes, 281b 657
March anemia, 301 characteristics, 285 amplicons and amplicon control measures, 655

Mar an’s syndrome, 507 clinical signs and symptoms, 284 ampli cation products analysis, 657–660, 658,
Marginal zone B-cell lymphoma, 430 epidemiology, 282–283 659, 660b
Marginating pool, 166 etiology, 282 consensus primer PCR, 657
Marrow stromal cells, 91 gastric pathology loop-mediated isothermal ampli cation

Mast cells, 91, 168, 169, 180 autoimmune gastritis, 284 (LAMP), 657
Mastocytosis, 468 ndings, 284 microarray gene chip technology, 665, 666
Material sa ety data sheet (MSDS) parietal cell, 284 nested primers, 656–657
accidental release measures, 710 pernicious anemia, 285 next-generation sequencing, 661–664, 663, 664

composition and in ormation on ingredients, hematological ndings, 281, 283 polymerase chain reaction, 655–656, 655b, 656,
709–710 laboratory ndings, 284–286 657t